K-134


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70


InChI Key	ULGNGSQNNMKROG-WOJBJXKFSA-N
Smiles	O=C(NCCCOc1ccc2[nH]c(=O)ccc2c1)N(C1CC1)[C@@H]1CCCC[C@H]1O
InChI	InChI=1S/C22H29N3O4/c26-20-5-2-1-4-19(20)25(16-7-8-16)22(28)23-12-3-13-29-17-9-10-18-15(14-17)6-11-21(27)24-18/h6,9-11,14,16,19-20,26H,1-5,7-8,12-13H2,(H,23,28)(H,24,27)/t19-,20-/m1/s1

Mechanism of Action	Action	Reference
Phosphodiesterase 3 inhibitor	INHIBITOR	Other


Protein: Phosphodiesterase 3 Description: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3B Organism : Homo sapiens Q13370 ENSG00000152270











Protein: Phosphodiesterase 3 Description: cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A Organism : Homo sapiens Q14432 ENSG00000172572

Assay Description	Organism	Bioactivity
In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 10 mg/kg (p.o.)	Mus musculus	88.0 %
In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 30 mg/kg (p.o.)	Mus musculus	100.0 %	In vivo anti-thrombotic activity was evaluated by the inhibition of pulmonary thromboembolism model in mice at a dose of 30 mg/kg (p.o.)	Mus musculus	100.0 %
In vivo anti-hyperplastic activity was evaluated by the inhibition of balloon injury model in rats at a dose of 10 mg/kg (p.o.)	Rattus norvegicus	26.0 %
In vivo anti-hyperplastic activity was evaluated by the inhibition of balloon injury model in rats at a dose of 30 mg/kg (p.o.)	Rattus norvegicus	24.0 %	In vivo anti-hyperplastic activity was evaluated by the inhibition of balloon injury model in rats at a dose of 30 mg/kg (p.o.)	Rattus norvegicus	29.0 %

CONTENTS